Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222891 · ClinicalTrials.gov registry record · Phase 2
Impact of Smell Testing on Health Outcomes
A Phase 2 study, sponsored by Monell Chemical Senses Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
NCT07222891 is a Phase 2 study that has not yet begun recruiting, run by Monell Chemical Senses Center. The registered enrollment target is 1,000 participants.
The verdict
NCT07222891, a Phase 2 study, has not yet begun recruiting, sponsored by Monell Chemical Senses Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.
Interventions
- BEHAVIORAL Patient-centered information and education
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222891
The ClinicalTrials.gov registry entry for NCT07222891 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Monell Chemical Senses Center, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patient-centered information and education is the first listed.
NCT07222891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07222891 about?
NCT07222891 is a clinical study titled "Impact of Smell Testing on Health Outcomes". Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to ...
What is the current status of trial NCT07222891?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2025-11-01. Estimated completion is 2027-11-30.
What interventions are being tested in trial NCT07222891?
The interventions under investigation include: Patient-centered information and education (BEHAVIORAL).
Who is sponsoring clinical trial NCT07222891?
This trial is sponsored by Monell Chemical Senses Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.